Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

NCT ID: NCT01563796

Last Updated: 2025-09-26

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 1115 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2016-10-15

Brief Summary

The objective of this study is to use a DEK ELISA to quantitatively measure DEK protein in the urine of patients suspected of having bladder cancer. The measurement of urine DEK protein, relative to an established cut-off, is correlated with the presence or absence of bladder cancer.

Detailed Description

Sample Collection:

Urine samples used in the study will be collected immediately prior to the urological evaluation procedure and stored at -80 oC. Urine samples will be sent to sponsor and remain at -80o C until analysis.

Clinical Data Collection:

All subject and clinical information will be recorded on the form in section 9.3. Enrollment Checklist and Case Report Form (CRF). Information regarding the history of hematuria and urine cytology will be recorded. In addition, non-identifying information including age, sex, race, smoking history, alcohol consumption, occupational exposure to chemicals or dyes, history of urologic disorder or disease, history of irritative voiding symptoms, history of urinary tract infection, history of pelvic irradiation, and analgesic abuse will be recorded. The Investigators will also be asked to provide information from the subjects' medical records for up to one (1) year after their enrollment and sample collection. In particular, diagnosis of TCC, other malignant diseases, or non-malignant urogenital conditions will be provided.

Conditions

Hematuria; Dysuria; Bladder Cancer

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

TCC positive

subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology

No interventions assigned to this group

TCC negative

subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients who are at least twenty-five (25) years of age with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones.

Exclusion Criteria

• Females who are pregnant (ascertained by history)
• Females who are menstruating or within three (3) days of their last menstruation
• Patients who have undergone invasive procedures of the urogenital tract in the past two (2) months
• Patients with a history of transitional cell carcinoma (TCC) of the urinary tract

• Minimum Eligible Age: 25 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical Diagnostic Laboratories, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jason Trama, PhD

Role: STUDY_DIRECTOR

Medical Diagnostic Laboratories, LLC

Locations

Staten Island University Hospital

Staten Island, New York, United States

Countries

United States

References

Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 2011 Jun 10;11:234. doi: 10.1186/1471-2407-11-234.

Reference Type: BACKGROUND

PMID: 21663673 (View on PubMed)

Other Identifiers

ONC04

Identifier Type: -

Identifier Source: org_study_id